First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trialLin Shen, Lin Xie, Xiangyu Gao et al.|Nature Medicine|2025Cited by 89
Author Correction: First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trialLin Shen, Lin Xie, Yanqiao Zhang et al.|Nature Medicine|2025Cited by 2